Armata Pharmaceuticals (ARMP) Interest Expenses (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Interest Expenses data on file, last reported at $58.4 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 1521.24% year-over-year to $58.4 million; the trailing twelve-month figure through Mar 2026 stood at $58.4 million (up 86.52% YoY), and the FY2025 full-year result was $97.8 million, up 16.1% from the prior year.
• Interest Expenses rose to $58.4 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $69.6 million in Q2 2024 to a low of $1452.0 in Q4 2022.
• A 5-year average of $18.2 million and a median of $5.2 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 1075382.09% in 2023 and sank 91.94% in 2025, its largest moves.
• Tracing ARMP's Interest Expenses over 5 years: stood at $1452.0 in 2022, then soared by 1075382.09% to $15.6 million in 2023, then sank by 44.06% to $8.7 million in 2024, then slumped by 85.21% to $1.3 million in 2025, then jumped by 4419.89% to $58.4 million in 2026.
• Business Quant data shows ARMP's Interest Expenses at $58.4 million in Q1 2026, $1.3 million in Q4 2025, and $61.0 million in Q3 2025.